Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 179,726 shares at $15.59 ($2.7M) on 2025-03-20, disclosed to the SEC on 2025-03-20.
Open-market purchase of $2.7M RNAC by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.42 | 14,740 | $213K | 7.8% |
| 2 | $14.42 | 14,740 | $213K | 7.8% |
| 3 | $14.97 | 20,234 | $303K | 11.0% |
| 4 | $14.97 | 20,234 | $303K | 11.0% |
| 5 | $15.59 | 54,889 | $856K | 31.2% |
| 6 | $15.59 | 54,889 |
| $856K |
| 31.2% |
| Total | $15.26 avg | 179,726 | $2.7M | 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |
| RNAC | BUY | 2025-01-15 | $660K | — | Filing → |